en · de · es · fr · pt
cardarine-notes.peptides6579.com › Faq › Detection, Regulation, And Quality Context — Reference Sheet

Detection, Regulation, And Quality Context — Reference Sheet

By Editorial Desk · published 2025-11-19 · last reviewed 2025-12-28 · Faq

carcinogenicity is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2025-12-28. Numbers and descriptions here follow the published literature rather than marketing material.

Detection, Regulation, and Quality Context

Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.

Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.

Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.

Identity and Regulatory Status

Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.

Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.

Cardarine at a glance

PropertyValueNotes
WADA classificationS4 Hormone and Metabolic ModulatorsProhibited at all times in sport.
Drug approval statusNot approved in major jurisdictionsNo accepted therapeutic indication.
Common detection methodLC-MS/MSDetects parent compound and metabolites.
Typical test matrixUrine or bloodUrine is common in anti-doping testing.
Product labelingResearch chemical or supplementOften not independently verified.

Detection, Stability, and Quality

Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.

Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.

Related pages on this site

Regulatory Status and Detection Context

Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.

Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.

A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.

Preclinical Findings and Safety Signals

Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.

Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.

Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.

Background from the literature

== Religion == At the New York Public Library in May 2007, Hitchens debated Al Sharpton on the issue of theism and anti-theism, giving rise to a memorable exchange about Mormonism in particular. In God is Not Great, Hitchens contended that,

=== Overdose issues === In 2007, a nurse at Cedars-Sinai Medical Center mistakenly gave the 12-day-old twins of actor Dennis Quaid a dose of heparin that was 1,000 times the recommended dose for infants. The overdose allegedly arose because the labeling and design of the adult and infant versions of the product were similar. The Quaid family subsequently sued the manufacturer, Baxter Healthcare Corp., and settled with the hospital for $750,000. Prior to the Quaid accident, six newborn babies at Methodist Hospital in Indianapolis, Indiana, were given an overdose. Three of the babies died after the mistake. In July 2008, another set of twins born at Christus Spohn Hospital South, in Corpus Christi, Texas, died after an accidentally administered overdose of the drug. The overdose was due to a mixing error at the hospital pharmacy and was unrelated to the product's packaging or labeling. As of July 2008, the exact cause of the twins' death was under investigation. In March 2010, a two-year-old transplant patient from Texas was given a lethal dose of heparin at the University of Nebraska Medical Center. The exact circumstances surrounding her death are still under investigation.

== External links == Basel, Yochai; Hassner, Alfred (2001). "Imidazole and Trifluoroethanol as Efficient and Mild Reagents for Destruction of Excess Di-tert-butyl Dicarbonate [(BOC)2O]". Synthesis. 2001 (4): 0550. doi:10.1055/s-2001-12350. S2CID 97029361.

Sources: en.wikipedia.org

Reference notes

== Identification in biological samples == A gas chromatography–mass spectrometry (GC–MS) method for the determination of fenethylline and related substances in plasma, urine, and hair has been developed, suggesting that hair testing can be useful for determining a drug history of fenethylline, and discrimination between fenethylline and its precursor, amphetamine.

== S == Salmonella Salmonella enteritidis Salmonella typhi Salmonella typhimurium Serratia marcescens Shewanella algae Shigella Shigella dysenteriae Shigella sonnei Spirillum volutans Staphylococcus Staphylococcus aureus Methicillin-resistant Staphylococcus aureus Staphylococcus epidermidis Staphylococcus lugdunensis Staphylococcus saprophyticus Stenotrophomonas maltophilia Streptococcus Streptococcus agalactiae Streptococcus anginosus Streptococcus avium Streptococcus bovis Streptococcus constellatus Streptococcus cricetus Streptococcus ferus Streptococcus intermedius Streptococcus lactis Streptococcus mitior Streptococcus mitis Streptococcus mutans Streptococcus oralis Streptococcus pneumoniae Streptococcus pyogenes Streptococcus rattus Streptococcus salivarius Streptococcus sobrinus Streptomyces avermitilis

=== N05CP Herbal hypnotics and sedatives === N05CP01 Valerian root N05CP02 Kava-kava rootstock N05CP03 St. John's wort N05CP04 Melissa herb N05CP05 Passionflower herb N05CP06 Valerian oil N05CP07 Hops N05CP30 Combinations N05CP50 Other herbal hypnotics and sedatives, combinations N05CP51 Valerian oil, combinations N05CP52 Kava-kava rootstock, combinations

=== Analogues === α-Methyltryptophan (αMTP) and α-methyl-5-hydroxytryptophan (α-Me-5-HTP) are prodrugs of αMS which cross the blood–brain barrier and thus efficiently deliver αMS into the central nervous system. As a result, these compounds act as orally bioavailable false or substitute neurotransmitters for serotonin, and have been suggested as possible therapeutic agents in the treatment of disorders where serotonin is deficient. The O-methylated analogue of αMS, 5-MeO-αMT (α,O-dimethylserotonin; α,O-DMS), also readily enters the brain, and could be used for such purposes as well.

Sources: en.wikipedia.org

Frequently asked questions

How is cardarine detected in anti-doping tests?

Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.

Is cardarine legal?

Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.

What does a certificate of analysis show?

A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.

Is cardarine a SARM?

No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.

Network